| Line Item | 2025-11-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | -100.0% |
| Cost of Revenue | $0 | — | -100.0% |
| Gross Profit | $0 | — | -100.0% |
| R&D Expense | $671K | — | -65.6% |
| SG&A Expense | $902K | — | -1.8% |
| Operating Income | -$1.6M | — | +41.5% |
| Income Tax | $2K | — | — |
| Net Income | -$1.6M | — | +41.0% |
| EPS (Diluted) | -$0.07 | — | +56.3% |
| Line Item | 2025-11-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $4.3M | — | — |
| Short-term Investments | $143K | +0.0% | +259.3% |
| Accounts Receivable | $88K | -76.1% | -66.6% |
| Current Assets | $5.4M | +54.6% | -39.2% |
| Total Assets | $6.1M | +44.9% | -38.2% |
| Current Liabilities | $1.5M | -2.5% |
| Line Item | 2025-11-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$984K | — | +63.9% |
| Capital Expenditures | $0 | — | -100.0% |
| Investing Cash Flow | -$5K | — | +86.5% |
| Financing Cash Flow | $3.5M | — | -20.1% |
| Free Cash Flow | -$984K | — | +64.2% |
| +389.1% |
| Total Liabilities | $1.5M | -2.9% | +282.1% |
| Stockholders' Equity | $4.9M | +64.3% | -49.7% |